



ICLUSIG® - Third Line Therapy for Chronic Myeloid Leukemia and Acute Lymphocytic Leukemia

Myeloid cells help produce red blood cells, platelets, and most types of white blood cells. Chronic Myeloid Leukemia occurs when an abnormal production of myeloid cells causes them to enter the blood stream and invade other organs such as the spleen. An increased myeloid cell count will result in a decreased normal blood cell count.

Acute Lymphoblastic Leukemia refers to increased production of lymphoblasts, these cells are responsible for the formation of white blood cells. Excess lymphoblasts invade other organs via the blood stream and simultaneously repress normal blood cell count.

At present, chronic cases currently make up 15% of all leukemias while acute cases, the most common form of childhood leukemia, account for 20%.

Iclusig® works by blocking signals responsible for excessive cell division within bone marrow. Studies have shown a 62% response rate to Iclusig® in chronic patients and a 65% response rate in those with acute cases versus placebo. These trials revealed that patients were twice as likely to respond to Iclusig® compared to other drugs within the same class. The common side effects of Iclusig® include: rash, dry skin, abdominal pain, thrombocytopenia, neutropenia, and anemia.

The maximum dose of Iclusig® is 45mg once daily. The cost of Iclusig® is \$142.8 per 15 mg tablet, and \$331.6 per 45 mg tablet resulting in an average annual cost of therapy of \$145,259.05.

Drug Name	Iclusig®
Drug Ingredients	Ponatinib
Annual Cost	\$145,259.05
Coverage Details	Excluded for Open Drug Formularies. *Special Authorization

*ClaimSecure groups that subscribe to the Managed Formulary, Specialty Drug, and Stop Loss programs

If you require additional information, contact the ClaimSecure Inc. Clinical Services Department
Toll Free 1-888-479-7587 x 3014 or 905-949-3014

ClaimSecure Inc. reserves the right to amend in part, or in its entirety, its special authorization clinical guidelines.

